<div id="readability-page-1"><div>Bragar Eagel &amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Praxis (PRAX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Praxis and would like to discuss your legal rights, call Bragar Eagel &amp; Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel &amp; Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ:PRAX) on behalf of Praxis stockholders. Our investigation concerns whether Praxis has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study. On this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025. If you purchased or otherwise acquired Praxis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel &amp; Squire, P.C.: Bragar Eagel &amp; Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel &amp; Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzNPQ00zTVRFeE9UWTFJekl4TURBek9UZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVeE5qZzNPQ00zTVRFeE9UWTFJekl4TURBek9UZz0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTk2NWU1NjYtOGM2ZC00MTViLThiMjItNDgxMjgwNGU1YmQwLTExMTE5NjktMjAyNS0wOC0yMy1lbg==/tiny/Bragar-Eagel-Squire.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTk2NWU1NjYtOGM2ZC00MTViLThiMjItNDgxMjgwNGU1YmQwLTExMTE5NjktMjAyNS0wOC0yMy1lbg==/tiny/Bragar-Eagel-Squire.png"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="150" height="75" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg"/></div></div>

PRAX

Bragar Eagel & Squire, P.C. 正在代表可能遭受損失的股東調查 Praxis Precision Medicines, Inc.。此次調查的重點是 Praxis 在 2025 年第二季度財務結果公佈後，可能違反聯邦證券法的情況，該財務結果顯示其抗癲癇藥物研究中出現不良事件，導致股價下跌 5.55%。投資者被鼓勵聯繫該公司以瞭解法律選擇

PRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the Firm

PRAXIS 警報：Bragar Eagel & Squire, P.C. 正在代表 Praxis Precision Medicines 的股東進行調查，並鼓勵投資者與該公司聯繫